Jonathan Rubin - 25 Feb 2026 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role: SVP, Chief Medical Officer
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol: SUPN
Transactions as of: 25 Feb 2026
Net transactions value: -$34,216
Form type: 4
Filing time: 26 Feb 2026, 16:17:42 UTC
Previous filing: 25 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Rubin Jonathan	SVP, Chief Medical Officer	C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE	/s/ Timothy C. Dec, as attorney-in-fact	26 Feb 2026	0001836067

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SUPN	Common Stock	Award	$0	+1,250	+9.8%	$0.000000	14,016	25 Feb 2026	Direct
transaction	SUPN	Common Stock	Tax liability	$34,216	-675	-4.8%	$50.69	13,341	25 Feb 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SUPN	Restricted Stock Unit	Disposed to Issuer	$0	-1,250	-50%	$0.000000	1,250	25 Feb 2026	Common Stock	1,250		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
F2	Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
F3	These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.